Swedish Orphan Biovitrum AB

Public biopharmaceutical company fundraising activity in late June and early July was somewhat remarkable after the BIO International Convention in early June, during which drug developers and investo

A US Centers for Disease Control and Prevention panel’s divided endorsement of Merck & Co .’s Enflonsia (clesrovimab-cfor) for prevention of respiratory syncytial virus in infants suggests that p

The US Food and Drug Administration approved Merck & Co.’s Enflonsia (clesrovimab-cfor) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infa

England’s health technology assessment (HTA) institute, NICE, has recommended in favor of making Pfizer’s Hympavzi (marstacimab) available on the National Health Service for preventing severe hemophil